GENELUX Corp (GNLX) income statement
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$2.24+0.24 (+12.00%)
Close on Nov 18, 2026Market cap $101.35MP/E –Yield –
GENELUX Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -455275.0%
- Net margin
- -444950.0%
- Return on equity, FY2025
- -170.0%
Financial strength
- Current ratio
- 2.39
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 114.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.29
- Dividend yield
- –
See a number that looks wrong?